NYSE:ALC (Switzerland)
Business Description
Alcon Inc
Chemin de Blandonnet 8, Royce Bedward, Vernier, Geneva, CHE, 1214
Compare
Compare
Traded in other countries / regions
2U3.Germany
•
ALC.Mexico
•
ALC.Switzerland
•
0A0D.UK
•
ALC.USA
Description
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun-off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.22 | |||||
| Equity-to-Asset | 0.7 | |||||
| Debt-to-Equity | 0.23 | |||||
| Debt-to-EBITDA | 2.46 | |||||
| Interest Coverage | 5.73 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 3.31 | |||||
| Beneish M-Score | -2.51 | |||||
| WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 2.2 | |||||
| 3-Year EBITDA Growth Rate | 6.3 | |||||
| 3-Year FCF Growth Rate | -29.2 | |||||
| 3-Year Book Growth Rate | -7.7 | |||||
| Future 3-5Y Total Revenue Growth Rate Industry Rank | 8.06 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 57.86 | |||||
| 9-Day RSI | 65.62 | |||||
| 14-Day RSI | 64.35 | |||||
| 6-1 Month Momentum % | -7.92 | |||||
| 12-1 Month Momentum % | -3.19 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.18 | |||||
| Quick Ratio | 1.31 | |||||
| Cash Ratio | 0.43 | |||||
| Days Inventory | 180.78 | |||||
| Days Sales Outstanding | 63.77 | |||||
| Days Payable | 85.02 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.27 | |||||
| Dividend Payout Ratio | 0.12 | |||||
| Forward Dividend Yield % | 0.27 | |||||
| 5-Year Yield-on-Cost % | 0.27 | |||||
| 3-Year Average Share Buyback Ratio | -0.1 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 56.47 | |||||
| Operating Margin % | 7.91 | |||||
| Net Margin % | 5.38 | |||||
| ROE % | 2.39 | |||||
| ROA % | 1.65 | |||||
| ROIC % | 2.42 | |||||
| ROC (Joel Greenblatt) % | 11.36 | |||||
| ROCE % | 2.45 | |||||
| Years of Profitability over Past 10-Year | 2 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 86.24 | |||||
| Forward PE Ratio | 31.45 | |||||
| PE Ratio without NRI | 86.24 | |||||
| PEG Ratio | 45.39 | |||||
| PS Ratio | 4.65 | |||||
| PB Ratio | 2 | |||||
| Price-to-Tangible-Book | 24.96 | |||||
| Price-to-Free-Cash-Flow | 578.75 | |||||
| Price-to-Operating-Cash-Flow | 31.75 | |||||
| EV-to-EBIT | 68.75 | |||||
| EV-to-Forward-EBIT | 46.92 | |||||
| EV-to-EBITDA | 23.6 | |||||
| EV-to-Forward-EBITDA | 16.74 | |||||
| EV-to-Revenue | 5.04 | |||||
| EV-to-Forward-Revenue | 4.62 | |||||
| EV-to-FCF | 627.06 | |||||
| Price-to-Graham-Number | 9.77 | |||||
| Earnings Yield (Greenblatt) % | 1.45 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NYSE:ALC
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 8,550 | ||
| EPS (TTM) ($) | 0.934 | ||
| Beta | 0.81 | ||
| Volatility % | 29.64 | ||
| 14-Day RSI | 64.35 | ||
| 14-Day ATR ($) | 1.3899 | ||
| 20-Day SMA ($) | 74.1915 | ||
| 12-1 Month Momentum % | -3.19 | ||
| 52-Week Range ($) | 63.92 - 88.78 | ||
| Shares Outstanding (Mil) | 490.09 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Alcon Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||